Compounded four-peptide recovery/skin blend (BPC-157 + GHK-Cu + TB-500 + KPV)
KLOW is an informal combination of four peptides sold together to target tissue repair, recovery, skin health, and inflammation.
| Class / type | Compounded four-peptide recovery/skin blend (BPC-157 + GHK-Cu + TB-500 + KPV) |
|---|---|
| Category | Healing, Recovery & Immune |
| Status (Jul 2026) | Research use only |
Each component works on a different repair pathway: BPC-157 for soft-tissue and gut healing and angiogenesis, TB-500 for cell migration and wound closure, GHK-Cu for collagen/tissue remodeling, and KPV for calming inflammation. The blend itself is not studied as a unit.
Used in peptide communities for injury recovery, soft-tissue and joint healing, skin/wound repair, and inflammation control; no published human trial exists for the combined blend.
Anecdotal broad recovery, skin, and anti-inflammatory benefits, with users citing the convenience of a single combined product covering multiple repair pathways.
Not FDA-approved and untested as a combination; it inherits every component's risks, including the theoretical tumor/angiogenesis concern from BPC-157 and TB-500 (their healing effects grow new blood vessels, which a tumor could also exploit). Unregulated material adds purity, sterility, and dosing risks.
Users often report strong subjective recovery and skin benefits and view it as a convenient all-in-one stack, but sentiment is enthusiast-driven and not backed by human trials of the blend.
NOT FDA-approved. None of the four components is FDA-approved for human use; BPC-157, TB-500 and KPV were under FDA compounding review in 2026. The blend is not an approved medical protocol and is treated as research-use-only.